These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37410332)

  • 21. Statin intolerance.
    Ahmad Z
    Am J Cardiol; 2014 May; 113(10):1765-71. PubMed ID: 24792743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Statin intolerance.
    Laufs U; Scharnagl H; März W
    Curr Opin Lipidol; 2015 Dec; 26(6):492-501. PubMed ID: 26780003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antihyperlipidemic Medication Treatment Patterns and Statin Adherence Among Patients with ASCVD in a Managed Care Plan After Release of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol.
    Bellows BK; Olsen CJ; Voelker J; Wander C
    J Manag Care Spec Pharm; 2016 Aug; 22(8):892-900. PubMed ID: 27459651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Practical aspects in the management of statin-associated muscle symptoms (SAMS).
    Laufs U; Filipiak KJ; Gouni-Berthold I; Catapano AL;
    Atheroscler Suppl; 2017 Apr; 26():45-55. PubMed ID: 28434484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of Statin Use in a Real-World Population of Patients at High Cardiovascular Risk.
    Lin I; Sung J; Sanchez RJ; Mallya UG; Friedman M; Panaccio M; Koren A; Neumann P; Menzin J
    J Manag Care Spec Pharm; 2016 Jun; 22(6):685-98. PubMed ID: 27231796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative evaluation of statin effectiveness versus intolerance and strategies for management of intolerance.
    Soran H; France M; Adam S; Iqbal Z; Ho JH; Durrington PN
    Atherosclerosis; 2020 Aug; 306():33-40. PubMed ID: 32683135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of rosuvastatin 20 mg versus rosuvastatin 5 mg plus ezetimibe on statin side-effects in elderly patients with atherosclerotic cardiovascular disease: Rationale and design of a randomized, controlled SaveSAMS trial.
    Cha JJ; Hong SJ; Kim JH; Lim S; Joo HJ; Park JH; Yu CW; Lee PH; Lee SW; Lee CW; Moon JY; Lee JY; Kim JS; Park JS; Lee K; Lim SY; Na JO; Cho JM; Kim SY; Lim DS
    Am Heart J; 2023 Jul; 261():45-50. PubMed ID: 36934981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease.
    Rodriguez F; Maron DJ; Knowles JW; Virani SS; Lin S; Heidenreich PA
    JAMA Cardiol; 2017 Jan; 2(1):47-54. PubMed ID: 27829091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of the 2013 Cholesterol Guideline on Patterns of Lipid-Lowering Treatment in Patients with Atherosclerotic Cardiovascular Disease or Diabetes After 1 Year.
    Tran JN; Kao TC; Caglar T; Stockl KM; Spertus JA; Lew HC; Solow BK; Chan PS
    J Manag Care Spec Pharm; 2016 Aug; 22(8):901-8. PubMed ID: 27459652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suggested clinical approach for the diagnosis and management of 'statin intolerance' with an emphasis on muscle-related side-effects.
    Sivashanmugarajah A; Fulcher J; Sullivan D; Elam M; Jenkins A; Keech A
    Intern Med J; 2019 Sep; 49(9):1081-1091. PubMed ID: 31507054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in the management of statin myopathy.
    Gallo A; Perregaux J; Bruckert E
    Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):142-151. PubMed ID: 33278129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.
    Boekholdt SM; Hovingh GK; Mora S; Arsenault BJ; Amarenco P; Pedersen TR; LaRosa JC; Waters DD; DeMicco DA; Simes RJ; Keech AC; Colquhoun D; Hitman GA; Betteridge DJ; Clearfield MB; Downs JR; Colhoun HM; Gotto AM; Ridker PM; Grundy SM; Kastelein JJ
    J Am Coll Cardiol; 2014 Aug; 64(5):485-94. PubMed ID: 25082583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment Patterns, Statin Intolerance, and Subsequent Cardiovascular Events Among Japanese Patients With High Cardiovascular Risk Initiating Statin Therapy.
    Nagar SP; Rane PP; Fox KM; Meyers J; Davis K; Beaubrun A; Inomata H; Qian Y; Kajinami K
    Circ J; 2018 Mar; 82(4):1008-1016. PubMed ID: 29276211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Underprescribing of statin therapy in people with HIV at risk for atherosclerotic cardiovascular disease.
    Gallegos Aragon K; Ray G; Conklin J; Stever E; Marquez C; Magallanes A; Anderson J; Jakeman B
    Am J Health Syst Pharm; 2022 Nov; 79(22):2026-2031. PubMed ID: 35976174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Clinical Guide to Combination Lipid-Lowering Therapy.
    Russell C; Sheth S; Jacoby D
    Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SAMSON and the Nocebo Effect: Management of Statin Intolerance.
    Krishnamurthy A; Bradley C; Ascunce R; Kim SM
    Curr Cardiol Rep; 2022 Sep; 24(9):1101-1108. PubMed ID: 35759168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trial designs for statin muscle intolerance.
    Rosenson RS
    Curr Opin Lipidol; 2017 Dec; 28(6):488-494. PubMed ID: 28832369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Significant Facility-Level Variation in Utilization of and Adherence with Secondary Prevention Therapies Among Patients with Premature Atherosclerotic Cardiovascular Disease: Insights from the VITAL (Veterans wIth premaTure AtheroscLerosis) Registry7.
    Mahtta D; Lee MT; Ramsey DJ; Akeroyd JM; Krittanawong C; Khan SU; Sinh P; Alam M; Garratt KN; Schofield RS; Ballantyne CM; Petersen LA; Virani SS
    Cardiovasc Drugs Ther; 2022 Feb; 36(1):93-102. PubMed ID: 33400053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs.
    Takata K; Nicholls SJ
    Am J Cardiovasc Drugs; 2019 Apr; 19(2):113-131. PubMed ID: 30565156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Temporal changes in statin prescription and intensity at discharge and impact on outcomes in patients with newly diagnosed atherosclerotic cardiovascular disease-Real-world experience within a large integrated health care system: The IMPRES study.
    Anderson JL; Knowlton KU; May HT; Bair TL; Armstrong SO; Lappé DL; Muhlestein JB
    J Clin Lipidol; 2018; 12(4):1008-1018.e1. PubMed ID: 29703626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.